Approval extends existing U.K. indication for Joenja to eligible children aged 4 to 11 who weigh at least 27 kgJoenja is expected to become available to patients covered by the expanded indication in February 2027Marks another step in Pharming’s strategy to expand Joenja across age groups and international markets Leiden, the Netherlands, November 6, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announce
A rare-disease player with a stabilized core product is now targeting a market 26 times larger, fueled by cash generation that needs no external financing.
First clinical data for leniolisib in a larger group of PID participants beyond APDS, supporting the potential of targeted PI3Kδ inhibition to address immune dysregulationLeniolisib was well-tolerated, with benefits observed across multiple measures of immune dysregulation, including improvement in lymphoproliferation and positive trends in lung and liver disease markersAll participants who completed the study elected to continue receiving treatment in a long-term extension study Leiden, the Net
Detailed price information for Inventiva S.A. ADR (IVA-Q) from The Globe and Mail including charting and trades.
Pharming Group (PHAR) has appointed Chief Commercial Officer Leverne Marsh and Chief Financial Offic
If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or moreDecision follows recent approval of Joenja for children aged 4 to 11 years with APDS weighing at least 27 kgPDUFA target action date of January 30, 2027 Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration
Leniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results from a Phase II trial of leniolisib in CVID in Q4 2026 Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighti
Pharming Group N.V. (NASDAQ:PHAR) announced on September 11 that the U.S. Food and Drug Administration approved Joenja for children aged 4–11 with activated PI3K delta syndrome, or APDS, who weigh at least 27 kilograms. APDS disrupts immune function. The new 40 mg and 50 mg tablet strengths expand dosing options for Joenja, or leniolisib. The […]
FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be available in October Leiden, the Netherlands, September 11, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental
Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month of September: H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in
This is the newest page. Registered accounts read further back.